Your browser doesn't support javascript.
loading
Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).
Panizza, Benedict J; de Souza, Paul; Cooper, Adam; Roohullah, Aflah; Karapetis, Christos S; Lickliter, Jason D.
Afiliação
  • Panizza BJ; Department of Otolaryngology-Head and Neck Surgery, Princess Alexandra Hospital and Faculty of Medicine, University of Queensland, Brisbane, Australia. Electronic address: b.panizza@uq.edu.au.
  • de Souza P; Medical Oncology, University of Western Sydney, Sydney, Australia.
  • Cooper A; Medical Oncology, University of Western Sydney, Sydney, Australia.
  • Roohullah A; Medical Oncology, University of Western Sydney, Sydney, Australia.
  • Karapetis CS; Department of Medical Oncology, Flinders Medical Center and Flinders Center for Innovation in Cancer, Flinders University, Adelaide, Australia.
  • Lickliter JD; Nucleus Network, Melbourne, Australia.
EBioMedicine ; 50: 433-441, 2019 Dec.
Article em En | MEDLINE | ID: mdl-31810818
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diterpenos / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diterpenos / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article